PGWD: Integrating Personal Genome for Warfarin Dosing

详细信息    查看全文

• 作者：Yidan Pan ; Ronghai Cheng ; Zhoufang Li…
• 关键词：Warfarin ; Dosage ; Pharmacogenomics ; Genome interpretation
• 刊名：Interdisciplinary Sciences: Computational Life Sciences
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：8
• 期：1
• 页码：23-27
• 全文大小：640 KB
• 参考文献：1.Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165(10):1095–1106. doi:10.​1001/​archinte.​165.​10.​1095 PubMed CrossRef
  2.Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348(9025):423–428PubMed CrossRef
  3.Moyer TP, O’Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK et al (2009) Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 84(12):1079–1094. doi:10.​4065/​mcp.​2009.​0278 PubMed PubMedCentral CrossRef
  4.Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB et al (2002) PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res 30(1):163–165PubMed PubMedCentral CrossRef
  5.Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84(3):326–331. doi:10.​1038/​clpt.​2008.​10 PubMed PubMedCentral CrossRef
  6.Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352(22):2285–2293. doi:10.​1056/​NEJMoa044503 PubMed CrossRef
  7.Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329–2333. doi:10.​1182/​blood-2005-03-1108 PubMed CrossRef
  8.Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr et al (2007) Estimation of warfarin maintenance dose based on VKORC1 (\(-1639 \text{G}>\text{A}\) ) and CYP2C9 genotypes. Clin Chem 53(7):1199–1205. doi:10.​1373/​clinchem.​2006.​078139 PubMed CrossRef
  9.Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G et al (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109(6):2477–2480. doi:10.​1182/​blood-2006-08-038984 PubMed CrossRef
  10.Eriksson S, Berg LM, Wadelius M, Alderborn A (2002) Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. Assay Drug Dev Technol 1(1 Pt 1):49–59. doi:10.​1089/​1540658027610013​01 PubMed CrossRef
  11.Wen SY, Wang H, Sun OJ, Wang SQ (2003) Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol 9(6):1342–1346PubMed PubMedCentral CrossRef
  12.Bennett ST, Barnes C, Cox A, Davies L, Brown C (2005) Toward the 1000 dollars human genome. Pharmacogenomics 6(4):373–382. doi:10.​1517/​14622416.​6.​4.​373 PubMed CrossRef
  13.Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG et al (2008) An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 6(6):935–943. doi:10.​1111/​j.​1538-7836.​2008.​02959.​x PubMed CrossRef
  14.van Leeuwen Y, Rombouts EK, Kruithof CJ, van der Meer FJ, Rosendaal FR (2007) Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms. J Thromb Haemost 5(8):1644–1649. doi:10.​1111/​j.​1538-7836.​2007.​02610.​x PubMed CrossRef
  15.International Warfarin Pharmacogenetics C, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753–764. doi:10.​1056/​NEJMoa0809329 CrossRef
  16.Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363(4):301–304. doi:10.​1056/​NEJMp1006304 PubMed CrossRef
  
• 作者单位：Yidan Pan (1)
  Ronghai Cheng (1)
  Zhoufang Li (1)
  Yujun Zhao (1)
  Jiankui He (1)
  
  1. Department of Biology, South University of Science and Technology of China, Shenzhen, China
  
• 刊物主题：Computer Appl. in Life Sciences; Computational Biology/Bioinformatics; Statistics for Life Sciences, Medicine, Health Sciences; Theoretical and Computational Chemistry; Theoretical, Mathematical and Computational Physics; Computational Science and Engineering;
• 出版者：International Association of Scientists in the Interdisciplinary Areas
• ISSN：1867-1462

文摘

Warfarin is a drug normally used in the prevention of thrombosis and the formation of blood clots. The dosage of warfarin is strongly affected by genetic variants of CYP2C9 and VKORC1 genes. Current technologies for detecting the variants of these genes are mainly based on real-time PCR. In recent years, due to the rapidly dropping cost of whole genome sequencing and genotyping, more and more people get their whole genome sequenced or genotyped. However, current software for warfarin dosing prediction is based on low-throughput genetic information from either real-time PCR or melting curve methods. There is no bioinformatics tool available that can take the high-throughput genome sequencing data as input and determine the accurate dosage of warfarin. Here, we present PGWD, a web tool that analyzes personal genome sequencing data and integrates with clinical information for warfarin dosing. Keywords Warfarin Dosage Pharmacogenomics Genome interpretation